Medium-Term Outcomes of Cryoablation for Nonoperative Management of Clinical T1-2N0 ER-Positive/HER2-Negative Breast Cancer in Elderly or Comorbid Women.

Authors

José María Oliver Goldaracena, Vicenta Córdoba Chicote, María José Roca Navarro, Diego Garrido Alonso, Ylenia Navarro Monforte, Teresa Díaz de Bustamante, Fernando García Martínez, Jorge Rey Porras, Covadonga Martí Alvárez, José Ignacio Sánchez Méndez, Elisa York Pineda, Laura Yébenes Gregorio, Virginia Martínez Marín

Published in

Journal of vascular and interventional radiology : JVIR. Pages 109061. Sep 04, 2026. Epub Sep 04, 2026.

Abstract

To evaluate the medium-term oncologic outcomes of ultrasound-guided cryoablation as part of a nonoperative management strategy for elderly or comorbid women with clinical T1-2N0 estrogen receptor-positive/HER2-negative breast cancer.
This retrospective single-center study included 113 women (median age, 84 years; range, 56-96 years) with 125 clinical T1-2N0 estrogen receptor-positive/HER2-negative breast cancers (median tumor size, 17 mm; range, 5-48 mm) who underwent ultrasound-guided cryoablation as part of a nonoperative management strategy between May 2019 and July 2024. Follow-up consisted of semiannual ultrasound and annual mammography. Patients with biopsy-proven breast cancer recurrence were managed with rescue cryoablation. The primary endpoint was breast cancer recurrence. Secondary endpoints included axillary nodal recurrence, primary and secondary local control, and recurrence-free survival.
Median follow-up was 25.3 months (95% confidence interval [CI], 12.0-40.0 months). Continued endocrine therapy use was documented in 103 of 113 patients (91.1%). Breast cancer recurrence occurred in two patients (1.7%), both treated with rescue cryoablation; one subsequently developed multifocal ipsilateral breast recurrence with ipsilateral axillary nodal metastases. Primary local control, secondary local control, axillary nodal recurrence, and estimated 3-year recurrence-free survival rates were 98.2%, 99.1%, 0.8%, and 97.0%, respectively.
Ultrasound-guided cryoablation demonstrated encouraging medium-term oncologic outcomes as part of a nonoperative management strategy in elderly or comorbid women with estrogen receptor-positive/HER2-negative breast cancer. These findings support further prospective evaluation before broader clinical implementation.

PMID:
42697411
Bibliographic data and abstract were imported from PubMed on 05 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.